This closely reflected survival outcomes seen in IDH1/2-WT recurrent glioma patients treated i.t. with adenovirus vector gene therapy delivering IL-12.24 Additionally, the 50 ng rIL-12 dosage was chosen because it minimizes the risk of rIL-12-associated toxicity and allows for complementary therapies to further enhance the rIL-12-driven survival effect. This evidence concerns the gene IDH1 and glioma.